CytomX Therapeutics, Inc.: STATE STREET CORP discloses a stake of more than 5% (Schedule 13G)
Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.
State Street Corp. disclosed a stake exceeding 5% in CytomX Therapeutics Inc. via a Schedule 13G filing with the SEC (accession 0000093751-26-000642). The filing signals that the institutional investor has crossed the key 5% threshold that triggers passive-investor disclosure requirements. CytomX, a clinical-stage oncology biotech, now counts State Street among its major institutional holders. The exact share count and percentage were not specified in the filing headline. Investors will watch for further 13G amendments or 13D filings to gauge whether State Street's position is passive or active.
Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.
Named in this story
CytomX Therapeutics, Inc., State Street Corp